Abivax Stock price

Equities

ABVX

FR0012333284

Biotechnology & Medical Research

Real-time Euronext Paris 09:35:00 2024-03-28 am EDT 5-day change 1st Jan Change
13.32 EUR +0.30% Intraday chart for Abivax -2.06% +35.64%
Sales 2023 * 2.62M 2.83M Sales 2024 * 2.64M 2.86M Capitalization 835M 903M
Net income 2023 * -102M -110M Net income 2024 * -133M -144M EV / Sales 2023 * 237 x
Net cash position 2023 * 215M 233M Net cash position 2024 * 113M 122M EV / Sales 2024 * 273 x
P/E ratio 2023 *
-6.88 x
P/E ratio 2024 *
-5.16 x
Employees 26
Yield 2023 *
-
Yield 2024 *
-
Free-Float 84.85%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.30%
1 week-2.06%
Current month+5.21%
1 month+1.52%
3 months+33.47%
6 months-10.72%
Current year+35.64%
More quotes
1 week
13.00
Extreme 13
13.70
1 month
11.54
Extreme 11.54
13.84
Current year
9.35
Extreme 9.35
14.00
1 year
6.71
Extreme 6.71
19.70
3 years
5.60
Extreme 5.6
36.70
5 years
5.60
Extreme 5.6
39.00
10 years
3.87
Extreme 3.87
39.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 23-05-04
Director of Finance/CFO - 17-01-01
Chief Tech/Sci/R&D Officer - 23-02-28
Members of the board TitleAgeSince
Founder 65 13-12-03
Director/Board Member - -
Director/Board Member 56 23-07-10
More insiders
Date Price Change Volume
24-03-28 13.32 +0.30% 7 493
24-03-27 13.28 -0.45% 24,494
24-03-26 13.34 -0.74% 36,645
24-03-25 13.44 -0.88% 16,847
24-03-22 13.56 -0.29% 15,397

Real-time Euronext Paris, March 28, 2024 at 09:35 am EDT

More quotes
Abivax develops innovative treatments modulating the body's natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.28 EUR
Average target price
35.6 EUR
Spread / Average Target
+168.07%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Abivax - Euronext Paris